8-K: Clene Inc. Announces Significant Survival Benefit with CNM-Au8 in ALS Compassionate Use Programs

Clene Inc. reported a significant survival benefit for ALS patients treated with CNM-Au8 in compassionate use programs compared to historical controls.

Summary

• Clene Inc. has announced positive results from its compassionate use expanded access programs (EAPs) for CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS).
• The EAPs provided access to CNM-Au8 treatment for over 250 individuals with ALS.
• Two independent analyses showed a significant survival benefit for patients treated with CNM-Au8 compared to historical controls.
• One analysis showed a 68% decreased risk of all-cause mortality compared to PRO-ACT matched controls.
• Another analysis showed a 57% decreased risk of all-cause mortality compared to ALS Natural History Consortium matched controls.
• CNM-Au8 30 mg treatment was well-tolerated, with no serious adverse events attributed to the drug.
• The EAP data supports moving CNM-Au8 to Phase 3 testing in ALS.

Sentiment

Score: 9

Explanation: The document presents very positive results from the compassionate use programs, with significant survival benefits and good tolerability, suggesting a high likelihood of success in future trials and a positive outlook for the company.

Positives

• The study showed a significant survival benefit for ALS patients treated with CNM-Au8.
• The treatment was well-tolerated with no serious adverse events reported.
• The results support the advancement of CNM-Au8 to Phase 3 clinical trials.
• The data was collected from a large group of over 250 patients in real-world settings.
• The study used two independent control groups for comparison, strengthening the results.

Risks

• The results are from compassionate use programs, not controlled clinical trials, which may have limitations.
• The company's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates is a risk.
• Regulatory agencies may affect the initiation, timing and progress of clinical trials and marketing approval.
• The company's ability to achieve commercial success for its drug candidates, if approved, is not guaranteed.

Future Outlook

The company plans to move CNM-Au8 rapidly to Phase 3 testing in ALS, based on the positive EAP results.

Management Comments

• Merit Cudkowicz, MD, MSc, stated that this is one of a few therapies with positive Phase 2 data that must go forward to Phase 3 trials.
• Richard S. Bedlack Jr., MD, PhD, MS, noted that these EAP results help us better understand how people living with more advanced disease respond to treatment and that the data warrants consideration to be included in Clene's discussions with regulatory agencies.

Industry Context

The announcement is significant in the context of ALS treatment, as there are limited effective therapies available. The positive survival data from the EAPs could position CNM-Au8 as a promising treatment option.

Comparison to Industry Standards

• The PRO-ACT dataset, used for comparison, is the largest publicly available repository of longitudinal ALS clinical trial data, containing more than 12,000 records.
• The ALS/MND Natural History Consortium data set contained approximately 1,700 records of people living with ALS from researchers across nine academic sites.
• The 68% and 57% decreased risk of mortality are significant compared to historical controls, and are better than many other ALS treatments in development.
• The fact that the EAP participants were generally too advanced for clinical trials makes the results even more compelling, as it suggests the drug may be effective in a broader range of patients.

Stakeholder Impact

• Shareholders may react positively to the significant survival benefit data.
• ALS patients and their families may have increased hope for a new treatment option.
• Employees may be motivated by the positive results and the potential for future success.
• The company's reputation may be enhanced by the positive clinical data.

Next Steps

• Clene plans to move CNM-Au8 rapidly to Phase 3 testing in ALS.
• The company will likely discuss the EAP data with regulatory agencies.
• A third EAP in ALS is expected to commence enrollment in the first half of 2024.

Key Dates

Keywords

CNM-Au8, ALS, Amyotrophic Lateral Sclerosis, Compassionate Use Program, Expanded Access Program, Survival Benefit, Neurodegenerative Diseases, Mitochondrial Health, Clinical Trials, Mortality